Robatumumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRobatumumab
Drug Alias Namerobatumumabum罗妥木单抗洛巴妥木单抗SCHOOL-71745419-D12 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsSolid tumoursKidney NeoplasmsColorectal Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsSolid tumoursKidney NeoplasmsColorectal Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG